Glycosmedia

Diabetes News Service

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookies Policy
  • News
  • Archive
  • Categories & Tags
  • Journal Watch
  • Updates
  • Education
  • Reviews
  • About us ▼
    • About Glycosmedia
    • Editorial Team
    • Frequently asked questions
    • Comments
    • Press Releases
    • Disclaimer
  • Subscribe
  • Contact

Diabetes News

Tag: eGFR


Dissociation of Glycated Albumin and HbA1c Is Associated With a Decline of Glomerular Filtration Rate as Evaluated by Inulin Clearance

October 21st 2021

In conclusion, GA and HbA1c are dissociated by GFR reduction in patients with glycemic disorder, and eGFR and HbA1c may not provide an accurate measure of the risk of DKD. Thus, care is needed in evaluating glycemic control using HbA1c in patients with kidney dysfunction (Diabetes Care)

Categories: Nephropathy, News
Tags: eGFR, Glycated albumin, HbA1c

Categories: Nephropathy
Tags: eGFR, Glycated albumin, HbA1c

Overestimation of glomerular filtration rate calculated from creatinine as compared with cystatin C in patients with type 2 diabetes receiving sodium-glucose cotransportor 2 inhibitors

July 27th 2021

There was a discrepancy between eGFRcr and eGFRcys in patients with type 2 diabetes receiving SGLT2 inhibitors when compared with those not receiving SGLT2 inhibitors (Diabetic Medicine)

Categories: Medication, News
Tags: eGFR, SGLT2 inhibitors, Type 2 Diabetes

Categories: Medication
Tags: eGFR, SGLT2 inhibitors, Type 2 Diabetes

The relationship between eGFR slope and subsequent risk of vascular outcomes and all-cause mortality in type 2 diabetes: the ADVANCE-ON study

July 14th 2019

Our study supports the utility of eGFR slope in type 2 diabetes as a surrogate endpoint for renal outcomes, as well as a prognostic factor for identifying individuals at high risk of cardiovascular disease and all-cause mortality (Diabetologia)

Categories: Nephropathy, News
Tags: eGFR, Type 2 Diabetes

Categories: Nephropathy
Tags: eGFR, Type 2 Diabetes

Temporal variation of renal function in people with type 2 diabetes mellitus: a retrospective UK Clinical Practice Research Datalink cohort study

April 3rd 2019

Overall, eGFR declined over time, although there was considerable variation between GFR categories and individuals. This highlights the difficulty in prescribing many glucose‐lowering therapies, which require dose adjustment for renal function. The study also emphasizes the importance of regular monitoring of renal impairment in people with T2DM (Diabetes, Obesity and Metabolism)

Categories: Nephrology, News
Tags: eGFR, Type 2 Diabetes

Categories: Nephrology
Tags: eGFR, Type 2 Diabetes

Elevated baseline glomerular filtration rate (GFR) is independently associated with a more rapid decline in renal function of patients with type 1 diabetes

November 6th 2015

In patients with T1DM, higher baseline mGFR is associated with more rapid mGFR decline. Patients with high baseline mGFR who developed rapid mGFR decline had higher HbA1c measurements throughout the study. These findings are consistent with the concept that poor glycaemic control over time may be a determining factor for the rapid renal function decline observed in some hyperfiltering patients (Journal of Diabetes and Its Complications)

Categories: Nephropathy, News
Tags: eGFR, HbA1c, Type 1 Diabetes

Categories: Nephropathy
Tags: eGFR, HbA1c, Type 1 Diabetes

Potential Impact of Prescribing Metformin According to eGFR Rather Than Serum Creatinine

September 15th 2015

The use of eGFR or CrCl to determine metformin eligibility instead of sCr can expand the adult population with diabetes for whom metformin is likely safe, particularly among non-Hispanic blacks and men (Diabetes Care)

Categories: Medication, News
Tags: eGFR, metformin, serum creatinine

Categories: Medication
Tags: eGFR, metformin, serum creatinine

Estimating Glomerular Filtration Rate: Performance of the CKD-EPI Equation over time in Patients with Type 2 Diabetes

September 14th 2015

The CKD-EPI formula underestimates mGFR and the rate of decline of mGFR in patients with type 2 diabetes with a mGFR greater than 60ml/min/1.73m2. The association between LDL cholesterol, triglycerides, HbA1c, diastolic blood pressure and the difference between mGFR and eGFR warrants further study (Journal of Diabetes and Its Complications)

Categories: Nephropathy, News
Tags: eGFR, mGFR

Categories: Nephropathy
Tags: eGFR, mGFR

Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data

June 30th 2015

Creatinine-based eGFR and albuminuria should be taken into account for cardiovascular prediction, especially when these measures are already assessed for clinical purpose or if cardiovascular mortality and heart failure are outcomes of interest  (The Lancet Diabetes & Endocrinology)

Categories: Cardiovascular, News
Tags: albuminuria, creatinine, eGFR

Categories: Cardiovascular
Tags: albuminuria, creatinine, eGFR

Estimated glomerular filtration rate progression in UK primary care patients with type 2 diabetes and diabetic kidney disease: a retrospective cohort study

June 4th 2015

Only a minority of diabetic patients with DKD had quantitative albuminuria assessments. The relatively low proportion of DKD patients with ACEi or ARB prescriptions suggests a gap between healthcare practice and available scientific evidence during the study period. Increased albuminuria and older age were the most consistent predictors of subsequent eGFR decline (International Journal of Clinical Practice)

Categories: Nephropathy, News
Tags: albuminuria, eGFR

Categories: Nephropathy
Tags: albuminuria, eGFR

Subscribe

subscribe-iconFREE weekly updates by email Please CLICK HERE

Gold Sponsors

AstraZenecaNovo NordiskBoehringer IngelheimNapp Diabetes

Silver Sponsors

Abbott Diabetes CareWelsh Endocrinology and Diabetes Society (WEDS)About Ascensia Diabetes Care

FUNDING NOTICE

The Glycosmedia website and newsletter has been made possible with funding support from our sponsors. None of our sponsors have control over the content of the website, newsletter, apps, Twitter feed or RSS newsfeed.

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Advertisers

CRC Press

The organisations advertising in this section do not have any input into, or editorial control over the content of this website.

Categories

  • Audits
  • Bariatric
  • Biochemistry
  • Cardiovascular
  • Devices
  • Diagnosis
  • Diet
  • Education
  • Epidemiology
  • Genetics
  • Gestational
  • Guidance
  • Guidelines
  • Hepatology
  • Hypertension
  • Immunology
  • Management
  • Media
  • Medication
  • Meetings
  • Monitoring
  • Nephrology
  • Neuropathy
  • Nephropathy
  • Obesity
  • Ophthalmology
  • Paediatrics
  • Pathology
  • Pharma
  • Pharmacology
  • Physiology
  • Podiatry
  • Prediabetes
  • Prevalence
  • Prevention
  • Psychological
  • Reports
  • Research
  • Screening
  • Sponsorship
  • Technology
  • Testing
  • Transplantation
  • Treatment
  • Wound Care

To see all articles associated with a category just click on the category name.

Popular Tags

ADA BMI canagliflozin CGM CKD closed-loop COVID-19 dapagliflozin DPP4 DPP4 inhibitors Empagliflozin exenatide GLP-1 RA GLP1 glycaemic control HbA1c heart failure hyperglycemia hypoglycemia incretin insulin insulin pump Insulin resistance Ketoacidosis liraglutide metformin microvascular mortality NAFLD NICE pioglitazone retinopathy semaglutide SGLT2 inhibitors sitagliptin statin sulfonylureas Type 1 Diabetes Type 2 Diabetes Vitamin D

To see all articles associated with a tag just click on the tag name.

Complete list of Tags ››

Join us on Facebook

Join us on Facebook

Please share Glycosmedia:

Follow us on Twitter

My Tweets

mobileGlycosmedia is also available as an App:

For iPhone and iPad | For Android devices


Sponsorship and Advertising

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Copyright © 2022 Glycosmedia Partnership